Speech by the President of the Republic from the Sanofi Pasteur site in Marcy-l'Étoile.

France Emmanuel Macron · President of France

16 June 2020 · Sanofi Pasteur site in Marcy-l'Étoile, France

Context
Macron addressed Sanofi Pasteur employees and officials in Marcy-l'Étoile on June 16, 2020, to mark a €600M investment in vaccine research and production as France exited the acute COVID-19 phase.
Main themes
COVID-19 vaccine research and production, Sanofi investment announcement, French industrial sovereignty, economic recovery post-crisis, public health crisis response, pharmaceutical excellence, employment preservation, French vaccine heritage, Louis Pasteur legacy, public-private collaboration
Duration
~24 min
74th percentile
Words
2,862
74th percentile
Sentences
138
77th percentile
Readability
53
72nd percentile
Grade
10.9
31st percentile
Syntax
3.04
53rd percentile
Vocabulary
2.12
31st percentile

Translated from French

Content
Actors
Style

The broad sphere of national life a sentence belongs to. Every sentence has an Arena, so it is the denominator the other indices are read against.

Other
  • Economic 42%41%
  • Ceremonial 18%17%
  • Social 17%17%
  • Geopolitical 15%14%
  • Institutional 9%9%
  • Technological 0%0%
  • Environmental 0%0%
  • Not in focus 1%

138 sentences in 28 paragraphs

Ladies and gentlemen mayors,

Ladies and gentlemen elected officials,

Gentlemen leaders of Sanofi,

Dear Serge WEINBERG,

Dear Paul HUDSON,

Ladies and gentlemen, dear friends,

I am very happy to be here today at this moment when, as I told the French people two days ago, we are turning the page on the first act of the health crisis, the most acute phase. And to do so in front of all of you, even if the safety distances and the precautions still in place require us to take some measures, even if, I regret to say, so many employees who would have liked to be here cannot be. But we think of them, and I know, I see the general director of Sanofi France, the representatives who advocate for their causes. But being here among you is also a symbol because I wanted to thank you, Mr. Prefect of the Region, and through you, all those who serve the State, but all of you, ladies and gentlemen mayors, parliamentarians, for your mobilization on the ground every day during this acute phase of the crisis. You have truly been on the front lines, fighting to provide protections, to reassure, to allow the life of the Nation to continue in health security. And I also want to thank this second line that I have often mentioned, which is perfectly represented here at Sanofi.

You did not close any of your production sites during this crisis. All the women and men who work every day for Sanofi continued to come to work to produce because if we stopped producing medicines, what good would it do to treat? With sometimes the anxieties and constraints that were linked to the period, and you fought. And so I want to take this opportunity before we begin and celebrate to say thank you to each and every one of you for holding on during these times and for giving so much meaning to the life of the nation. The investment you just announced is more than 600 million euros in investments in research and production for vaccines. It is a wonderful bridge between the two axes, so to speak, and the battle we have to conduct. Sanofi has fully committed to the battle to find treatments and a vaccine against this Covid-19. And Sanofi is fully engaged in the economic battle that we have begun to launch in recent weeks. Because yes, while the health crisis is entering a less acute phase today, the economic crisis and the social consequences that arise from it are becoming fully perceptible to our fellow citizens. And it is therefore today that we must fight to fully revive the economy, investments to limit layoffs as much as possible, which, in some cases, will be inevitable, and restructurings. But also to regain activity, market shares, economic and industrial excellence, to build the independence and future of our Nation and to offer opportunities to our youth.

The project announced today consists of placing Sanofi and France at the heart of the excellence in the fight against the virus and to find a vaccine and help us win this battle for employment and industrial reconquest. This investment is not a matter of chance. It is first and foremost the result of recognition, that of industrial excellence and the women and men who have carried it for so many years, Mr. Director. And I say this in front of you with all those you represent. The women and men I had the opportunity to be with earlier have carried the industrial excellence of Sanofi for decades. I praised their commitment during this crisis, but your company has never abandoned industrial production; it has always believed in it. The 18 French industrial production sites show this, your European presence, your European strength, your international leadership in this area also demonstrate it. And you have never ceased to work, to believe in it, to carry this strength. I say this here very simply where sometimes some would like to oppose these causes: no social and health battle can be won if we do not win the battle of production and industry. Because we always finance what we redistribute with what we have first produced. And we do not win any economic battle if we do not believe in industry and industrial presence.

It is the constancy of these fundamentals that you carry that allows us today to invest more. And you are in this regard the worthy successors of Marcel MÉRIEUX, whose symbols are just behind us. His portrait, the carpet adorns the room that is just behind me. You have continued to produce, to seek, to innovate, and so this investment decided today is the fruit of this industrial history and the women and men who carry it. This investment is also the fruit of an entire territory. France is a great country of vaccines. I want to recall here the genius of Louis Pasteur, of whom Marcel MÉRIEUX was a student. Bringing excellence to us in both the public and private sectors. The Pasteur Institute has multiple successes; Sanofi and Sanofi Pasteur and this factory are proof of that. It is one of the largest vaccine factories in Europe. The symbol also that France is a great industrial nation in the medical field. 30,000 companies, 450,000 direct and indirect jobs, 90 billion in revenue, of which 40% is for export. And these productive sites in your territory are also the sign and trace of a local regional excellence that has endured over time and has always been maintained by this cooperation between the private sector and the public sector, between employees, entrepreneurs, and elected officials. This investment today is therefore for me an extremely strong act and proof of the importance of this independence that France must regain: technological, industrial, and health independence. Let us be clear, ladies and gentlemen. There will be, in the years to come, in the decades to come, other health crises. And we do not know where they will come from, but the risk is there and will continue to be present.

It is also for this reason that the decisions announced today and taken will help us respond to it and structure the future and our capacity to act. This crisis has shown us that we must continue to produce in our country and on our continent. That we must not depend, that we must regain a strategic vision of the value chain and be on the battles of today and tomorrow. This is what the investment decided today allows us to do. With just over 600 million euros in investment, here in Marcy-l’Etoile, an additional line will be decided. And an exceptional factory, a world first, the EVF vaccine factory, which will allow, in Neuville-sur-Saône, as you have perfectly explained just now, to produce quickly, digitally, much more efficiently all the vaccines we will need in the future, adapting according to the difficulties and requirements of the moment but especially with a production innovation that is absolutely unique. And this investment that you are deciding both in research and development and in production is proof that our country, our world leader can continue to believe in research and development and industrial production in our country for today or tomorrow. Several hundred jobs will be created at the end of this investment, and it is proof that what I explained to the French people two days ago is not simply a commendable intention but requires simply changing collectively the paradigms on which we were.

The paradigm of a spirit of defeat, of the fatality of a page that many wanted to turn. No. The future of France is not in the end of factories. No! The future of France is not in a world where we would produce less and work less. I do not believe it for a second. We will produce, work differently by innovating more, by creating the factory of the 21st century and not by going back to what prevailed in the past. But yes, it is through the will and industrial, productive, contemporary ambition that we will build our future. This investment, you said, is the fruit of exemplary cooperation in recent weeks, and I really want to thank you for this spirit of cooperation, you and all your teams. All the members of the Government who contributed to it, as well as the health authorities. We have collectively been able to decide and act quickly, and beyond the amounts, succeed in the battle for employment and the sovereignty of the independence I mentioned. It is about knowing how to decide and act quickly. We have also become far too accustomed to the idea that losing time and doing a lot of paperwork was a good way to move forward. We have demonstrated with this project the exact opposite. And so we must maintain this ability to decide quickly, to make strong decisions, and to move forward. Everyone knows it since this project has been in the air for three years and the region has been buzzing about it. And just a few weeks ago, this project could have been decided in Singapore. There is no fatality when we decide together with a sense of responsibility, which is what we have done.

We will go further in this sector in the coming days.

A first envelope of 200 million euros will thus be unlocked to finance production and research and development infrastructures to be able to respond to the needs of the time and health crises. This envelope will allow us, beyond this specific case, to support other projects for treatments and vaccines, particularly against Covid-19 and beyond.

We will, and this is the decision I have made, in light of what we have experienced during this crisis, develop a mechanism for planning, financing, and organizing French industrial resilience in health matters. What have I asked the Government through this? To try to anticipate future crises with much more depth and to see where all our vulnerabilities and dependencies are in terms of health organization and production. And through this planning work in connection with public research, private research, and our industrialists, to correct all our vulnerabilities and try either to repatriate or recreate production forces, whether it concerns active ingredients or our ability to organize in times of crisis. This is the very illustration of what I mentioned a few weeks ago to the French people: we must regain a sense of the long term and industrial strategy. By summer, we will finalize this planning, financing, and action mechanism.

Finally, starting Thursday, we will launch an initiative to relocate certain critical productions. Everyone saw during this crisis that medicines that seemed usual were no longer produced in France and Europe. Everyone saw it. And so we must, beyond asking ourselves the question, draw all the consequences. And I would like, with Sanofi, to continue in this spirit of partnership to fully re-engage in this dialogue, which is indeed win-win, where because we will invest in these relocation initiatives, we will take commitments. For example, we will be able to fully reproduce, package, and distribute paracetamol in France. We need to regain the capacity to do that.

And so, you have understood, the strong decision you made today, the envelope of 200 million to accelerate funding, the planning and organization mechanism, and the relocation initiative are the first axes of this French strategy to reclaim our full health and industrial sovereignty.

It will be done in partnership with our historical champion, with our champions, and the region counts a few others whose founders I salute. But it is clear that groups like the Mérieux group to the most contemporary startups, from pharma groups to digital in the sector are fully engaged in this adventure. And we will continue to move forward strongly in this area. This creates jobs, it creates industrial fabric, it creates independence for our country. But the independence I believe in is not a narrow sovereignism that would stutter history. We will always remain, in any case, in an open world and an open Europe. Being independent is simply choosing openness and not enduring it. Being independent means being able to withstand the crises we face in an open world. That is what we need to improve. But being independent is not about closing borders and wanting to become autarkic in France; that would be impossible. And so I believe in this strategic independence that marries with European and international cooperation. And that is why we will also continue to move forward.

France has spearheaded the ACT-A initiative that we launched during the crisis. We have convinced our European partners, many of our international partners, as well as numerous public and private funds committed to health. And the ACT-A initiative, built with the World Health Organization, allows for a major advancement in this area, with you as well. And I say this just a few kilometers from a city that will host the WHO international training center, which we hold dear and which will mark the commitment of the WHO to Lyon and to our country, beyond our cooperations. The ACT-A initiative that we have built will enable us, in terms of treatment, testing, improving primary health systems, and vaccines, to foster international cooperation among different countries and major pharmaceutical industries and companies. On the one hand, to have productive cooperation and competition to research this vaccine, but to ensure that access to the vaccines, once found, will be granted to the greatest number.

I advocate for this vision of a global public good for what the vaccine will be. It will obviously be necessary for research efforts to be rewarded, that is logical, but we must collectively fight through this initiative against any form of retention, which would be unacceptable, so that in certain less developed countries, there is no lack of access to the vaccine once found. ACT-A is the illustration of this marriage between our sovereignty, our independence, and cooperation in the health battle. And we wanted to translate this at the European level through a very concrete initiative called TIVA, which consists, along with Germany and Italy, the Netherlands, and the European Commission, in launching this inclusive alliance for the vaccine, tasked with negotiating with the main pharmaceutical laboratories to guarantee the supply of vaccines to the European population. A first agreement was concluded on Friday. I hope that we will succeed in concluding an agreement with Sanofi in the coming days or weeks.

But what is the objective of this initiative? To say we, Europeans, are coming together to ensure that whoever finds the vaccine, European as we wish, but also American and Chinese or elsewhere, we have the capacity together to produce it as quickly as possible for our population. This is what we owe to our fellow citizens. This is where European cooperation is obviously very strong, and this is also why the factory announced today makes perfect sense because this type of factory will allow us to move much faster and much stronger on this type of initiative.

You see, Europe is also here at the rendezvous. Nearly 10 billion euros for health are planned in the new budget proposal in which we will fight alongside the European parliamentarians who are here with me. And 2.4 billion euros in funding are reserved to help member states pre-finance the vaccines. The Europe of health, we are building it in action, and this Europe of health, we called for it right from the Franco-German agreement of May 18. It is also beginning to materialize in a very practical way.

That is why I am pleased, dear Paul Hudson, with this European and French ambition fully illustrated by your decision today. This afternoon, I will hold a videoconference with the vast majority of vaccine producers to engage everyone in this adventure. And you yourself said that you wanted to go further. We will be by your side, France and Europe, for this EVF+ vaccine factory as well as to mobilize all the funding for a second large-scale European project of cell cultures where antigens and monoclonal antibodies, which are part of the vaccine manufacturing process, would be produced.

We have the capacity to do it, and this crisis will give Europe and France the means sometimes to catch up and, I am sure, to get ahead.

So, Ladies and Gentlemen, this is what I wanted to tell you today beyond my preliminary thanks. The will announced two days ago finds its full realization here; and we will continue to move forward on this path together, that of conquest, industrial voluntarism, independence, economic and industrial reconstruction for employment, and European cooperation. It is in the DNA of this beautiful region, it is in the DNA of this fabric, of this department, and of this metropolis. It is also in the DNA of your company, at the heart of our country's project.

Thank you.

Thank you, Paul, and thank you to all your employees.

Thank you very much, thank you all.